Valsartan
- Generic Name
- Valsartan
- Brand Names
- Dafiro, Diovan, Diovan Hct, Entresto, Exforge, Exforge Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N5O3
- CAS Number
- 137862-53-4
- Unique Ingredient Identifier
- 80M03YXJ7I
- Background
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, olmesartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and syn...
- Indication
Valsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It is also indicated for the treatment of heart failure (NYHA class II-IV) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting ...
- Associated Conditions
- Cardiovascular Mortality, Diabetic Nephropathy, Heart Failure, Hypertension, Moderate Essential Hypertension, Chronic heart failure with reduced ejection fraction (NYHA Class II), Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Hospitalization due to cardiac failure
- Associated Therapies
- -
Effectiveness of a Valsartan Based vs an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy
- Conditions
- First Posted Date
- 2006-07-12
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 79
- Registration Number
- NCT00351130
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial (the DRAFT Trial)
- Conditions
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2008-08-21
- Lead Sponsor
- Intermountain Health Care, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT00343499
- Locations
- 🇺🇸
McKay Dee Hospital, Ogden, Utah, United States
🇺🇸LDS Hospital, Salt Lake City, Utah, United States
🇺🇸Dixie Regional Medical Center, St. George, Utah, United States
Comparative Study of Valsartan and Amlodipine Versus Amlodipine Alone in Hypertension
- Conditions
- First Posted Date
- 2006-06-05
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 551
- Registration Number
- NCT00333489
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
A Study to Evaluate the Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled on Monotherapy
- Conditions
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 894
- Registration Number
- NCT00327145
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)
- Conditions
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 582
- Registration Number
- NCT00311740
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Tokyo, Japan
Effectiveness of a Valsartan Based Versus an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy
- Conditions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1288
- Registration Number
- NCT00304226
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia
- Conditions
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2014-08-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 871
- Registration Number
- NCT00254475
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Diva - The Effects Of 12 Weeks Of Treatment With High Dose Valsartan (320 Mg) To Amlodipine On Endothelial Function In Hypertensive Subjects With The Metabolic Syndrome
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 80
- Registration Number
- NCT00241150
Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2012-05-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 27
- Registration Number
- NCT00241072
The VALIDATE Study of Valsartan for Patients With Early Stage Heart Failure
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 37
- Registration Number
- NCT00241098
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.